BridgeMD
Compares treatment options for Rectal Neoplasm Malignant
Official title Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
ClinicalTrials.gov ID: NCT03587480
What this study is testing
- What it's testing
- Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO). While Japanese scholars advocate total mesorectal excision (TME) plus lateral lymph node dissection (LLND), European and American scholars advocate TME alone after Neoadjuvant Chemo-radiotherapy (nCRT), without the need of LLND.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Histologically confirmed adenocarcinoma(below the peritoneal reflection) Clinical stage Ⅲ
- Tumor is capable of performing radical recession
- No past history of chemotherapy, pelvic radiation of other cancers.
- Written informed consent
- Lower tumor margin is confirmed below the peritoneal reflection
You likely can't join if
- Past history of other cancers
- Multiple Primary Colorectal Cancers or Familial adenomatous polyposis(FAP)
- Combine with inflammatory bowl disease(IBD)
- Recurrence tumor or invade other organs
- Combine with obstruction,perforation or bleeding which need emergency surgery.
- Local tumor invade the external sphincter, levator ani muscle or adjacent organs
See the full eligibility criteria
- Histologically confirmed adenocarcinoma(below the peritoneal reflection) Clinical stage Ⅲ
- Tumor is capable of performing radical recession
- No past history of chemotherapy, pelvic radiation of other cancers.
- Written informed consent
- Lower tumor margin is confirmed below the peritoneal reflection
- Clinical state T(1-3)N(1-2)M0 is confirmed by the multiple disciplines team(MDT) including surgeons,diagnostic radiologist,radiation oncologist and medical oncologists base on MRI and endorectal ultrasound -
- Past history of other cancers
- Multiple Primary Colorectal Cancers or Familial adenomatous polyposis(FAP)
- Combine with inflammatory bowl disease(IBD)
- Recurrence tumor or invade other organs
- Combine with obstruction,perforation or bleeding which need emergency surgery.
- Local tumor invade the external sphincter, levator ani muscle or adjacent organs
- Participant join other clinical trials in 4 weeks.
- American Society of Anesthesiologists(ASA) ≥Ⅳ and/or Eastern Cooperative Oncology Group(ECOG) ≤2
- Pregnant or lactating patients
- Severity infection before operation
- Psychological disorder
- Severe dysfunction of organs or other contraindications
- Cardiac infarction within six months
- Severe pulmonary emphysema and pulmonary fibrosis
- Doctor's decision for exclusion
- Operative findings: Tumor invade other organs Lower tumor margin is above the peritoneal reflection
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.